Recent advances in the total synthesis of agelastatins by Dong, Guangbin
2231
Pure Appl. Chem., Vol. 82, No. 12, pp. 2231–2246, 2010.
doi:10.1351/PAC-CON-10-08-04
© 2010 IUPAC, Publication date (Web): 4 October 2010
Recent advances in the total synthesis of
agelastatins*
Guangbin Dong
Division of Chemistry and Chemical Engineering, California Institute of Technology,
Pasadena, CA 91125, USA
Abstract: Agelastatins represent an important family of marine alkaloids in terms of both
exceptional biological activity and intriguing chemical structure. In this article, the isolation
and biological activity of agelastatins are reviewed, and proposed biosynthetic pathways are
summarized. The main focus is given to comparative evaluation of recent total syntheses,
mainly of agelastatin A. To date, this has been accomplished by 11 research groups. Their
synthetic routes are analyzed and summarized, with a view to furnishing the reader with
insight into different strategic design approaches to assembly of a densely functionalized and
compact structure.
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INTRODUCTION
As treasure from the ocean, marine sponges constitute a rich source for medicinally important natural
products. Among various structurally intriguing secondary metabolites, pyrrole-imidazole alkaloids
represent an important class, which exhibits a vast range of biological properties [1]. This is exempli-
fied by the agelastatins, which have remarkable anticancer activity. Given their significance, both in
terms of biological activity and the challenge posed by their structural complexity, numerous synthetic
approaches have been explored during the past decade. Although some of the earlier efforts have been
covered in part of a review by Weinreb in 2007 [2], a tremendous amount of more recent synthetic
investigation has been disclosed during the past four years, which has been additionally stimulated by
more recent oncology studies during 2008 [3] and isolation of new agelastatins during 2010 [4]. For
example, in 2009 alone, no less than six publications appeared on the total syntheses of agelastatin A.
This article aims to outline a historical review on the isolation, biology, and synthesis of this fascinat-
ing family of natural products. Particular attention will be drawn to those strategies that highlight the
dramatic impact of synthetic efficiency on overall results.
ISOLATION AND BIOLOGICAL ACTIVITY
Agelastatin A (1) was originally isolated by Pietra et al. in 1993 from the axinellid sponge Agelas den-
dromorpha collected in the Coral Sea near New Caledonia [5] (Fig. 1). A minor congener was isolated
as agelastatin B (2) with an additional bromo substituent at C(14). Conformational preferences and the
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absolute configuration of agelastatin A were determined by semisynthetic derivation, molecular mod-
eling, and spectroscopic analysis [6,7]. In addition to structural verification arising from earlier total
synthesis, the structure of 1 was unambiguously determined through X-ray crystallography of material
isolated from Mexican Agela sp. by Pettit [8]. Agelastatins C (3) and D (4) were isolated from the West
Australian sponge Cymbastela sp. by Molinski and co-workers in 1998 [9]. Agelastatin C contains an
extra hydroxyl group at C(4); whereas agelastatin D lacks an N(1) methyl group. Very recently (2010),
agelastatins E (5) and F (6) were isolated as minor components from a butan-1-ol extract of the New
Caledonian sponge A. dendromorpha, along with agelastatin A [4]. Agelastatin E is formally O-methyl -
agelastatin A; while agelastatin F is 14-bromoagelastatin D. The question whether agelastatin E is a nat-
ural product has not yet been addressed [4]. As indicated in Pietra’s initial semi-synthesis work [6] (later
confirmed by Movassaghi’s seminal total synthesis [10]), treatment of 1 in the presence of Amberlyst
15 and MeOH results in methanol exchange at C(8), giving O-methylagelastatin A, the 1H NMR spec-
trum of which is identical to that of agelastatin E (eq. 1). Thus, there is a possibility that compound 5
was formed during the purification process.
Among various oroidin-family alkaloids that have been isolated, agelastatin A was the first to
exhibit exceptional cytotoxicity toward a range of cancer cell lines, including human KB nasopharyn-
geal cancer cells (IC50 = 0.075 μg/ml), L1210 murine tumor cell line, RT112/84 bladder carcinoma
cells, SK-MEL-5 melanoma cells, HCT-116 colon carcinoma cells, and MDA-MB-435s breast cancer
cells [8,11]. In many cases, agelastatin A was shown to be 1.5 to 16 times more potent than the front-
line chemotherapeutic agent cisplatin, but with low toxicity [3]. Recent oncology studies by Hale and
co-workers have shown that agelastatin A inhibits osteopontin-mediated adhesion, invasion, and colony
formation, suggesting that it can serve as a potent anti-invasive agent [3]. Two mechanisms have been
suggested for the antimetastatic activity of agelastatin A: (1) it blocks the Wnt signal pathway; (2) it
can arrest cancer cells in the G2 phase of the cell cycle.
Agelastatin A also exhibits a number of other important activities. For example, it selectively
inhibits glycogen synthase kinase-3β (GSK-3β) in the presence of casein kinase 1, CDK1/cyclin B, and
CDK5/p25 at low concentration (IC50 = 12 μM), suggesting a potential approach for the treatment of
Alzheimer’s disease [11]. Hale et al. have suggested that agelastatin A might also function as a novel
G. DONG
© 2010, IUPAC Pure Appl. Chem., Vol. 82, No. 12, pp. 2231–2246, 2010
2232
Fig. 1 Agelastatins.
(1)
insulin mimetic [13]. In addition, agelastatin A has been reported to possess potent activity against brine
shrimp (LC50 = 1.7 ppm), larvae of beet armyworm, and corn rootworm [9].
Structure–activity relationship (SAR) studies indicate that 5-OH, 3-NH, and 9-NH functionality
is essential for the cytotoxicity of agelastatin A [7], since alkylation or acylation of any of these sites
leads to significant loss of activity. The 13-bromo group is also considered to be important for optimal
activity because its absence results in an increase of IC50 value against L1210 cells from 0.033 to
0.143 μg/ml. It is noteworthy that other naturally occurred agelastatins B–F show dramatically dimin-
ished biological activity by comparison with agelastatin A (1), indicating that the unique pattern of
functionality in agelastatin A, and, perhaps, derived conformational properties may be decisive.
SYNTHETIC CHALLENGES AND BIOLOGICAL SYNTHETIC PATHWAY
In addition to its appealing biological activity, the structure of agelastatin has also been attractive to the
synthetic community. The general structural features can be summarized in terms of three 4-fold char-
acteristics, thus: 
(1) Four rings. All agelastatins contain an unusual 5-6-5-5 fused tetracylic ring system, including an
A-ring bromopyrrole motif, a B-ring piperazinone, a C-ring cyclopentane, and a D-ring imida-
zolone (urea).
(2) Four stereocenters. Agelastatin contains four contiguous stereocenters, all of which are located
on the five-membered C-ring.
(3) Four nitrogen atoms. Each of these stereogenic centers bears a nitrogen atom. Stereoselective
introduction of a nitrogen functionality can be very challenging.
Besides agelastatin’s unique structure, early semisynthetic efforts by Pietra have indicated some addi-
tional challenges and provided inspirations for the total synthesis [7]:
(1) The C(13) bromine atom can be simply cleaved in the presence of sodium hydride or LAH.
(2) The C(5) hydroxyl group can be eliminated by treatment of dry warm pyridine or Amberlyst 15
in CHCl3 to give imidazolones 8 (eq. 2).
(3) The C/D ring junction was found to have certain flexibility during an effort in hydrolyzing imi-
dazolones 8. The C(4), C(5) epimers (9) were observed in a mixture along with the natural iso-
mers (7) (eq. 3).
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Two biosynthetic pathways have been suggested. Pietra proposed a cascade route starting from a
hymenidin-like precursor 10 (Scheme 1A) [5]; while Mourabit prefers to begin with an oxidized
hymenidine precursor (12) that can proceed through a cyclization to install the C-ring, which can
undergo pyrrole-participated conjugated addition to provide the tetracycle skeleton (Scheme 1B) [14].
Note that Mourabit’s proposal relies on multiple imine-enamine tautomerizations.
TOTAL SYNTHESES OF AGELASTATINS
To date, 11 groups have completed the total synthesis of agelastatin and a variety of strategies have been
employed. Given that the D-ring of agelastatin can be assembled by spontaneous cyclization from a
ketone intermediate (eq. 4), focus will be given to the strategic design on the construction of the fused
ABC-ring tricycle.
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Scheme 1 Biosynthetic pathway.
(4)
Weinreb’s racemic synthesis of agelastatin A (1999)
Weinreb's group accomplished the first total synthesis of racemic agelastatin A in 1999 [15]. Their strat-
egy for the ABC-ring synthesis is illustrated in Scheme 2. The B-ring would be constructed in the end
of the synthesis via participation of the pyrrole terminus of a bicyclic precursor in an intramolecular
Michael addition. Disconnection at N(9)–C(10) bond reveals amide intermediate 18, which would be
synthesized by acylation of a C-ring-containing compound (19).
In a forward sense, Weinreb’s synthesis beautifully utilized pericyclic reactions multiple times to
construct the polyfunctionalized C-ring (Scheme 3). It was first used in an N-sulfinyl-mediated
Diels–Alder reaction, second in a [2,3]-sigmatropic rearrangement to launch the C(5)–O and C(4)–N(3)
bonds, and third in a Kresze-type ene reaction [16] to introduce the C(8)–N(9) bond. With amine 19 in
hand, acylation with 2-trimethylsilyl (TMS) pyrrole acyl chloride, followed by a chemoselective hydrol-
ysis of cyclic carbamate and pyridinium dichromate (PDC) oxidation led to enone 18. Treatment of
enone 18 with Cs2CO3 provided the ABC-ring tricycle (17). Note that the TMS group was purposely
employed as a surrogate for the labile C(13) bromine atom. Weinreb’s route has set a high-level bench-
mark for the total synthesis of agelastatin A, and this strategy, especially the use of 1,4-addition to
assemble the B-ring core, has been employed by many following efforts. 
© 2010, IUPAC Pure Appl. Chem., Vol. 82, No. 12, pp. 2231–2246, 2010
Recent advances in the total synthesis of agelastatins 2235
Scheme 2 Weinreb’s assembly strategy.
Scheme 3 Weinreb’s racemic synthesis of agelastatin A.
Feldman’s syntheses of (–)-agelastatins A and B (2002)
The first enantioselective syntheses of (–)-agelastatins A and B were accomplished by Feldman’s group
in 2002 [17]. The general strategy for the ABC-ring assembly is illustrated in Scheme 4. Similar to
Weinreb’s strategy, the B-ring was constructed at the very end of the synthesis via an elegant one-pot
alcohol oxidation–sulfone elimination–Michael addition sequence; the amide precursor 26 was ulti-
mately derived from acylation of amide 27.
In a forward manner, Feldman’s synthesis can be highlighted by two novel aspects: (1) utilization
of alkynyliodonium salts and (2) multiple usage of sulfone functionality. Starting from chiral epoxide
28, alkynyliodonium salt 30 can be prepared by treatment of stannane 29 using Stang’s reagent
(Scheme 5) [18]. Upon nucleophilic addition of p-toluenesulfinate salt, the resulting alkylidene-carbene
31 underwent a diastereoselective C–H insertion to give the agelastatin C-ring along with some
1,2-migration product 33. Subsequently, vinyl sulfone serves as a Michael acceptor to allow installation
of the N(9) group. After an acylation–hydrolysis process, treatment of alcohol 26 under Moffat–Swern
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Scheme 4 Feldman’s assembly strategy.
Scheme 5 Feldman’s enantioselective syntheses of (–)-agelastatins A and B.
oxidation conditions [19] furnished ABC tricycle 24, which can be transformed to either agelastatin A
or B in two steps. Note that Feldman’s synthesis represents the first synthesis of agelastatin B, and this
late-stage bromination protocol has been adopted by many others.
Hale’s formal and total synthesis of (–)-agelastatin A (2003 and 2004)
Hale and co-workers completed a formal total synthesis of (–)-agelastatin A in 2003 [20] along with a
new total synthesis in 2004 [21]. Both syntheses utilized a similar strategy for the ABC-ring construc-
tion as the one in Weinreb’s synthesis, but in an asymmetric fashion. Hale’s route initiates with chiral
aziridine 34 (Hough–Richardson aziridine), which can be prepared in 5 steps from a sugar derivative
(Scheme 6). Upon a 10-step sequence, a ring-closing metathesis (RCM) was employed for the C-ring
closure providing compound 36. Transformation of intermediate 36 to carbamate 37 followed by a
4-step elaboration afforded cyclization precursor 38. (–)-Agelastatin A was then achieved in 4 steps
from 38. The RCM strategy employed in Hale’s strategy has been utilized by many others in the age-
lastatin C-ring synthesis. 
Davis’s synthesis of (–)-agelastatin A (2005)
A concise asymmetric synthesis of (–)-agelastatin A was developed by Davis’s group in 2005 [22], and
the yields of certain steps were improved in 2009 [23]. A similar 1,4-addition was employed for the
B-ring closure to install the ABC-ring tricycle (Scheme 7). In Davis’ strategy, the A-ring pyrrole was
introduced first followed by formation of the C-ring through olefin metathesis. The RCM precursor
would ultimately be synthesized from diamine 42.
© 2010, IUPAC Pure Appl. Chem., Vol. 82, No. 12, pp. 2231–2246, 2010
Recent advances in the total synthesis of agelastatins 2237
Scheme 6 Hale’s asymmetric synthesis of agelastatin A.
Scheme 7 Davis’s assembly strategy.
Davis’ synthesis is featured by high efficiency in stereocontrol and functionality introduction.
Utilizing acrolein-derived chiral sulfinimine 43, two nitrogen-containing stereocenters were beautifully
introduced in one step, and the reactivity of the two nitrogens was differentiated by different protecting
groups (Scheme 8). Upon acylation with pyrrole-2-carboxylic acid, diene 41 was obtained in just a few
steps. The RCM reaction went uneventfully to furnish the C-ring affording the Michael addition pre-
cursor 40. A three-step elaboration (1,4-addition, deprotection-urea formation, and bromination) led to
the final product (–)-agelastatin A. 
Du Bois’s synthesis of (–)-agelastatin A (2006)
An efficient route to (–)-agelastatin A was accomplished by Du Bois and Wehn in 2006 [24]. Their
strategy for ring assembly is distinct from the previous ones (Scheme 9): the B-ring would be installed
at a late stage via an amide formation; the A-ring pyrrole would be introduced from Paal–Knorr con-
densation from polyfunctionalized amine precursor 47. 
The Du Bois group has extensively developed elegant methodology based on stereoselective
Rh-catalyzed intramolecular aziridination reactions. The efficacy of this methodology has been nicely
illustrated in this synthesis (Scheme 10). Chiral sulfamate 49 was prepared in high yield over three steps
from lactam (–)-48. The RhII-catalyzed aziridination was achieved in excellent yield and diastereo -
selectivity with low catalyst loading. With a rigid tricycle 50 in hand, two functionalities can be sequen-
tially introduced: first, the aziridine was selectively opened with azide at the internal position; second,
a selenide attacked at the external C–O bond after an N-acylation. Such a sequence beautifully set up
all the required stereocenters providing amine 47. Paal–Knorr condensation was then employed for the
A-ring synthesis to afford pyrrole 52. A three-step sequence was next used to furnish the D-ring urea
(46). Treatment of intermediate 46 under basic conditions followed by bromination ultimately led to
(–)-agelastatin A. 
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Scheme 8 Davis’s synthesis: A chiral sulfinimine strategy.
Scheme 9 Du Bois’s assembly strategy.
Trost’s stereodivergent synthesis of both (+)- and (–)-agelastatin A (2006)
In 2006, Trost and Dong developed a stereodivergent strategy to access both enantiomers of  agelastatin
A [24,25]. Aiming to provide a general access to various nitrogen-containing natural products, a new
class of nucleophiles, pyrroles, and N-alkoxyamides (hydroxamic esters) is developed for the Pd-cat-
alyzed asymmetric allylic alkylation (AAA) reactions. These new tools allow rapid construction of
 agelastatin tricycle core with excellent chemo-, diastereo-, and enantioselective control (Scheme 11).
For the synthesis of (+)-agelastatin A, amino-ketone 53 could be derived via olefin functionalization
from tricycle 54. Piperazinone 54 would be accessed via a stepwise allylic alkylation: first introduction
of the pyrrole N–C bond and then the amide N–C bond. For the synthesis of (–)-agelastatin A, tricycle
56 would be envisioned as the precursor to provide ent-53. A one-pot cascade reaction was designed
between bis-electrophile 58 and bis-nucleophile 59b to generate the ABC-ring tricycle in just one step.
A unique aspect of Trost’s strategy is represented by the capability to access either tricyclic piper -
azinone regioisomer (54 or 56) from similar starting materials.
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Scheme 10 Du Bois’s synthesis: A Rh-catalyzed aziridine route. 
Scheme 11 Trost’s assembly strategy.
In a forward fashion, the Pd-catalyzed AAA between pyrrole 59a and carbonate 58 provided
adduct 60 in good yield and high enantioselectivity (Scheme 12). (R,R)-LST (standard Trost ligand) was
employed as the asymmetric ligand for Pd catalyst. After elaboration of the methyl ester to
methoxyamide, a second Pd-catalyzed alkylation led to a high-yielding cyclization to tricycle piperazi-
none 54. Transformation of the olefin to the requisite amino-ketone was effected by two new catalytic
systems: an NHC-copper-catalyzed aziridination and an InIII-catalyzed regioselective oxidative open-
ing of an aziridine with dimethyl sulfoxide (DMSO). The N-heterocyclic carbene (NHC)–Cu complex
later proved to be an effective and general catalyst for aziridination of electron-deficient olefins [26].
The (+)-agelastatin A was ultimately completed by acylation of 53 with methyl isocyanate followed by
reductive cleavage of N-OMe and N-Ts groups.
A concise synthesis of the (–)-agelastatin A has been achieved. Employment of nucleophile 59b
containing both pyrrole and methoxyamide resulted in a one-pot double allylic alkylation. Piperazinone
tricycle 56 was obtained in 83 % yield and 97.5 % ee, which indicated that the methoxyamide serves
as a stronger nucleophile than the pyrrole under these conditions. The same chiral ligand (R,R)-LST was
utilized again for the enantioselective control, and use of acetic acid as a catalytic additive proved to be
crucial. Introduction of the N(3) group was achieved by an allylic amination (Kresze reaction [16]);
subsequent acylation followed by formal hydration of the olefin resulted in urea 63, which was elabo-
rated to (–)-agelastatin A in two steps.
Some distinctive features are noteworthy in Trost’s synthesis: (1) it represents the only agelastatin
synthesis to date that utilizes a chiral catalyst to control the absolute stereochemistry; (2) it utilizes the
same enantiomer of a stereoinducing catalyst to obtain either enantiomer of agelastatin A, and the two
complementary routes differ only in the choice of nucleophile in the Pd AAA reactions; (3) it is the first
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Scheme 12 Trost’s stereodivergent synthesis of both product enantiomers of agelastatin A.
agelastatin synthesis that introduces C(13) bromine atom at an early stage of the synthesis; (4) this syn-
thesis necessitated development of new catalytic systems, but these also offer scope for general and
widespread application. 
Ichikawa’s synthesis of (–)-agelastatin A (2007)
Ichikawa’s group reported an asymmetric synthesis of agelastatin A in 2007 (Scheme 13) [27]. Similar
to Weinreb and Hale’s syntheses, this one also employed an intramolecular Michael addition to install
the B-ring and an acylation for connection of A,C-rings (see Scheme 2). Ichikawa’s synthesis is fea-
tured by a double usage of a [3,3]-sigmatropic rearrangement of allyl cyanate, which proves to be an
effective strategy for [1,3]-chirality transfer and oxygen/nitrogen exchange. Starting from L-arabitol,
two of the chiral C–O bonds can be sequentially replaced with C–N bonds. Carbamate 64 was next
transformed to its corresponding allyl cyanate 65, which can undergo subsequent [3,3]-sigmatropic
rearrangement to give more stable isocyanate 66. Elaboration of 66 to diol 67 set the stage for an RCM
to generate the C-ring of agelastatin. Transformation of diol 68 to carbamate 69 required additional four
steps. The same cyanate formation and [3,3]-rearrangement can be applied again to give protected
amine 70. Further elaboration resulted in cyclopentenone Michael-precursor 71, which was ultimately
converted to (–)-1 in four steps.
Yoshimitsu–Tanaka’s synthesis of (–)-agelastatin A (2008 and 2009)
The Yoshimitsu–Tanaka group accomplished a total synthesis of (–)-agelastatin A in 2008 [28] and an
improved approach in 2009 [29]. Their strategy for the ABC-ring construction has some common
aspects with Du Bois’s route (Scheme 14): (1) the B-ring was formed at the end of the synthesis; (2)
the N(3) and N(9) functionalities were introduced via an intramolecular aziridination reaction; (3) the
A-ring pyrrole was assembled via Paal–Knorr condensation. 
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Scheme 13 Ichikawa’s synthesis of (–)-agelastatin A.
Scheme 14 Yoshimitsu–Tanaka’s assembly strategy.
In a forward manner, chiral Boc-protected amine 75 was prepared in six steps from cyclopenta-
diene. The pyrrole A-ring was installed after removal of the Boc group (Scheme 15). A C1 unit was
introduced by treatment of pyrrole 74 with trichloroacetyl isocyanate. Three steps were taken to trans-
form the amide group to a nitrile and introduce the azidoformate group. Heating compound 77 at 160 °C
under high pressure provided the desired aziridine 73 in 92 % yield, which then underwent ring-open-
ing by an azide to give compound 73. A three-step elaboration led to formation of the agelastatin B-ring.
The resulting tetracyclic intermediate 72 was converted to the natural product in another three steps. 
In 2009, a second-generation strategy was developed to enhance the efficiency of the transforma-
tion of amide 76 to tetracycle 72, in which four steps are saved. An FeII-mediated radical cyclization, a
method developed by Bach in 2000, was employed as the key step to offer bromo amide 80 [30].
Subsequent treatment of amide 80 with NaH provided lactam 72, which serves as the common inter-
mediate in their previous route.
Wardrop’s synthesis of racemic agelastatin A (2009)
In 2009, the Wardrop group developed an elegant synthesis of racemic agelastatin A [31]. Their syn-
thesis is featured by multiple usage of a trichloroacetamide group: first as a substrate of Overman
rearrangement to install the N(3) group (Scheme 16, 80); second as a nucleophile in the 5-exo-trig
cyclo functionalization for later introduction of the N(9) group; third as an amine protecting group;
fourth as a urea surrogate, such as in compound 83. A four-step elaboration of urea 83 resulted in enone
84, which then functioned as a precursor for an intramolecular Michael addition. Subsequent debenzyl -
ation and bromination afforded racemic agelastatin A. 
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Scheme 15 Yoshimitsu–Tanaka’s two-generation synthesis of (–)-agelastatin A.
Chida’s synthesis of (–)-agelastatin A (2009)
In 2009, another asymmetric synthesis of (–)-agelastatin A was reported by Chida and co-workers [32].
Similar to the strategies of Weinreb, Feldman, Hale, Ichikawa, and Wardrop, this synthesis also focuses
on a de novo synthesis of the polysubstituted C-ring core. Chida’s route is highlighted by multiple tan-
dem sigmatropic rearrangements. Starting from commercially available chiral acetonide 85, diene 86
was prepared in seven steps (Scheme 17). Treatment of diene 86 with a base at 140 °C led to two tan-
dem stereoselective Overman rearrangements, providing vicinal diamine 88. Oxidation of the sulfide to
allylic sulfoxide resulted in a subsequent [2,3]-sigmatropic rearrangement, and product 89 is struc-
turally analogous to Hale’s intermediate 35. An RCM strategy was then used to introduce the C-ring
followed by a cyclization to give oxazoline 90. A seven-step sequence was next employed to prepare
the Michael addition precursor 91. Treatment of enone 91 with a base followed by debenzylation pro-
vided (–)-agelastatin A.
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Scheme 16 Wardrop’s synthesis: A trichloroacetamide strategy.
Scheme 17 Chida’s synthesis: A strategy with tandem sigmatropic rearrangements. 
Movassaghi’s synthesis of (–)-agelastatins A–F (2010)
The most recent work comes from Movassaghi’s group, in which a highly concise synthesis of (–)-age-
lastatins A–F was accomplished [10]. Movassaghi’s strategy was initially inspired by the biosynthesis
of these natural products, and a clever route was adopted (Scheme 18). Unlike previous syntheses, they
decided to construct the C-ring at the very end of the synthesis via a 5-exo-trig cyclization; the inter-
mediate 92 would come from hemiaminal 93. The D-ring imidazolone would be derived from an ester
group; cleavage of the C(8)–N(9) bond disclosed that the B-ring would be formed from bisester 95.
In a forward manner, chiral amide 95 could be prepared in three straightforward steps from
D-aspartic acid dimethylester (96). Treatment of amide 95 with NaBH4 in MeOH followed by addition
of TsOH in MeOH resulted in a tandem lactam formation/imide reduction. Three transformations are
required to convert the methyl ester to the requisite imidazolone: (1) formation of a thioester; (2) a
Cu-mediated ketone synthesis using ureastannane 99 as the nucleophile; (3) dehydration with HCl in
MeOH. The resulting imidazolones 93a and 93b serve as key intermediates for agelastatin synthesis.
Remarkably, reaction of 93a with a strong Brønsted acid in water afforded (–)-agelastatin A (1) in 47 %
yield, along with C3,C4 epimer 97 (24 % yield). (–)-Agelastatin B (2) can be readily derived from 1 in
84 % yield. Heating epimer 97 in dry pyridine led to nearly quantitative conversion to imidazolone 8,
an intermediate that has been observed in Pietra’s semisynthesis [7]. Oxidation of the tetrasubstituted
olefin with dimethyldioxirane (DMDO) gave the C3,C4-epi-agelastatin C (98), which can undergo an
acid-mediated equilibration to provide (–)-agelastatin C (3) in 41 % yield. 
In a similar fashion, (–)-agelastatin D (4) was prepared from imidazolone 93b albeit in 26 %
yield, and bromination of 4 uneventfully gave (–)-agelastatin F (6) in 86 % yield. Adopting a known
procedure [6], conversion of (–)-agelastatin E (5) from 1 was secured in 96 % yield. Therefore,
Movassaghi’s synthesis provides a unified route for access of all the known agelastatin alkaloids
(Scheme 19). Several unique features are noteworthy: 
(1) Practicality. This synthesis represents one of the most concise syntheses of 1 with high yielding
and scalability (gram-scale preparation). 
(2) Structure confirmation. For the first time, structures of 2 and 4 were confirmed by X-ray crystal-
lography, and structures of 3 and 6 were confirmed by total synthesis. 
(3) Inspiration. Movassaghi’s synthesis provides an important implication to the biosynthesis of the
agelastatin family, especially on the pivotal role of the C(13) bromine atom.
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Scheme 18 Movassaghi’s assembly strategy.
CONCLUSION
This review highlights recent efforts toward the total synthesis of agelastatin A, a highly potent anti-
cancer agent, and other agelastatins. To date, 11 research groups have accomplished elegant syntheses
of this marine alkaloid; and during these syntheses, various new methods and graceful strategies have
been developed. These methods and strategies have provided valuable lessons not only for the produc-
tion of agelastatins, but also for the synthesis of numerous other related alkaloid natural products. 
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